BL1107 failed to replicate visual function improvements seen in an earlier, smaller study, prompting the company to redirect resources toward a sustained-release implant for geographic atrophy
Newsflash:
Optimized dosing regimen achieved steady-state drug levels nine weeks earlier than in the trial’s first phase, as …
BL1107 failed to replicate visual function improvements seen in an earlier, smaller study, prompting the company to redirect resources toward a sustained-release implant for geographic atrophy
Optimized dosing regimen achieved steady-state drug levels nine weeks earlier than in the trial’s first phase, as …
BL1107 failed to replicate visual function improvements seen in an earlier, smaller study, prompting the company to redirect resources toward a sustained-release implant for geographic atrophy
Optimized dosing regimen achieved steady-state drug levels nine weeks earlier than in the trial’s first phase, as …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
BlueRock Therapeutics reports that a single transplant of dopaminergic progenitors derived from pluripotent stem cells produced durable reductions in motor disability in Parkinson’s patients, with Phase 3 enrolment underway
BlueRock Therapeutics reports that a single transplant of dopaminergic progenitors derived from pluripotent stem cells produced durable reductions in motor disability in Parkinson’s patients, with Phase 3 enrolment underway
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
BL1107 failed to replicate visual function improvements seen in an earlier, smaller study, prompting the company to redirect resources toward …
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Listen Now
Data presented at AAIC 2026 tie SEMA4D blockade to regulation of astrocyte biomarkers linked to disease progression, as the company scopes an enlarged SIGNAL-AD2 trial
Optimized dosing regimen achieved steady-state drug levels nine weeks earlier than in the trial’s first phase, as the biotech positions its lead antibody for late-stage development
BL1107 failed to replicate visual function improvements seen in an earlier, smaller study, prompting the company to redirect resources toward a sustained-release implant for geographic atrophy
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, highlighting the regulatory tightrope in advanced therapeutics.
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?